Brought to you by 
Pharming repurchases royalty rights from Paul Royalty
13 Sep 2018
Executive Summary
Pharming Group NV has given Paul Royalty Fund royalty rights to recombinant human C1 inhibitor (rhC1INH), a therapeutic candidate in Phase III for hereditary angioedema.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharming repurchases royalty rights from Paul Royalty
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice